ImmunoPrecise Antibodies EBITDA 2022-2025 | IPA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ImmunoPrecise Antibodies ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ImmunoPrecise Antibodies ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Veeva Systems (VEEV)	$37.2B
Hims & Hers Health (HIMS)	$15B
Tempus AI (TEM)	$13.5B
Inspire Medical Systems (INSP)	$5.3B
IRhythm Technologies (IRTC)	$3.5B
Privia Health (PRVA)	$3.1B
Enovis (ENOV)	$2.5B
Clover Health Investments (CLOV)	$2.3B
Azenta (AZTA)	$2.1B
Schrodinger (SDGR)	$1.9B
Omnicell (OMCL)	$1.9B
Phreesia (PHR)	$1.7B
10x Genomics (TXG)	$1.5B
Butterfly Network (BFLY)	$1B
Talkspace (TALK)	$652M
Fulgent Genetics (FLGT)	$531M
Standard BioTools (LAB)	$517M
TruBridge (TBRG)	$426M
Nyxoah SA (NYXH)	$357M
Health Catalyst (HCAT)	$338M
SOPHiA GENETICS SA (SOPH)	$319M
Pulmonx (LUNG)	$262M
American Well (AMWL)	$191M
EUDA Health Holdings (EUDA)	$102M
MDxHealth SA (MDXH)	$88M
P3 Health Partners (PIII)	$77M
111 (YI)	$69M
CareCloud (CCLD)	$63M
HeartBeam (BEAT)	$58M
Outset Medical (OM)	$50M